Joseph K. Belanoff's most recent trade in Corcept Therapeutics Inc was a trade of 12,959 Common Stock done at an average price of $84.6 . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 84.57 per share. | 02 Jun 2025 | 12,959 | 2,910,393 (2%) | 0% | 84.6 | 1,095,962 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.01 per share. | 02 Jun 2025 | 8,408 | 2,901,985 (2%) | 0% | 85.0 | 714,778 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.42 per share. | 02 Jun 2025 | 4,881 | 2,937,104 (2%) | 0% | 78.4 | 382,773 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.46 per share. | 02 Jun 2025 | 4,631 | 2,923,352 (2%) | 0% | 83.5 | 386,523 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.48 per share. | 02 Jun 2025 | 3,050 | 2,934,054 (2%) | 0% | 79.5 | 242,421 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 80.30 per share. | 02 Jun 2025 | 2,988 | 2,931,066 (2%) | 0% | 80.3 | 239,941 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.33 per share. | 02 Jun 2025 | 1,820 | 2,929,246 (2%) | 0% | 81.3 | 148,012 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.26 per share. | 02 Jun 2025 | 1,263 | 2,927,983 (2%) | 0% | 82.3 | 103,899 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.22 per share. | 02 May 2025 | 21,520 | 2,941,985 (2%) | 0% | 73.2 | 1,575,776 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.52 per share. | 02 May 2025 | 18,480 | 2,963,505 (2%) | 0% | 72.5 | 1,340,146 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.72 per share. | 31 Mar 2025 | 35,102 | 2,982,335 (2%) | 0% | 94.7 | 3,324,861 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 114.71 per share. | 31 Mar 2025 | 350 | 2,981,985 (2%) | 0% | 114.7 | 40,149 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.83 per share. | 24 Mar 2025 | 1,974 | 3,017,437 (2%) | 0% | 60.8 | 120,084 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 350,000 | 350,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.91 per share. | 28 Feb 2025 | 2,924 | 3,019,411 (2%) | 0% | 60.9 | 178,098 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | 31 Dec 2024 | 348,811 | 2,831,918 (2%) | 0% | 0 | Common Stock | ||
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | 31 Dec 2024 | 348,811 | 190,417 (0%) | 0% | 0 | Common Stock | ||
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | 31 Dec 2024 | 190,417 | 3,022,335 (2%) | 0% | 0 | Common Stock | ||
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | 31 Dec 2024 | 190,417 | 0 (0%) | 0% | 0 | Common Stock | ||
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.29 per share. | 31 Jul 2024 | 450,000 | 798,811 (0%) | 0% | 3.3 | 1,480,500 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 450,000 | 0 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.67 per share. | 31 Jul 2024 | 259,583 | 539,228 (0%) | 0% | 38.7 | 10,038,075 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 500,000 | 500,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 800,000 | 0 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 06 Jul 2022 | 800,000 | 800,000 (0%) | 0% | 2.1 | 1,664,000 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.21 per share. | 06 Jul 2022 | 451,189 | 348,811 (0%) | 0% | 26.2 | 11,825,664 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.27 per share. | 06 Jul 2022 | 279,908 | 2,538,218 (2%) | 0% | 26.3 | 7,352,008 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.26 per share. | 06 Jul 2022 | 55,111 | 2,483,107 (2%) | 0% | 26.3 | 1,446,945 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2022 | 500,000 | 500,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 800,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.42 per share. | 22 Jan 2021 | 800,000 | 3,299,214 (2%) | 0% | 4.4 | 3,536,000 | Common Stock |
| Corcept Therapeutics Inc | Joseph K. Belanoff | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.06 per share. | 22 Jan 2021 | 481,088 | 2,818,126 (2%) | 0% | 28.1 | 13,499,329 | Common Stock |